

THRU E-MAIL

April 4, 2023

The Secretary
BSE Ltd.
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023
corp.relations@bseindia.com

The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051
takeover@nse.co.in

Dear Sir,


Re: Declaration under Regulation 31 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 - Krebs Biochemicals & Industries Ltd.-
(Scrip code: BSE: 524518 and NSE: KREBSBIO)

Pursuant to Regulation 31 (4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we hereby declare that we have not made any encumbrance, directly or indirectly, on shares held by us in Krebs Biochemicals & Industries Ltd. other than those already disclosed during the financial year ended 31st March, 2023.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish Kamath
Corporate Counsel & Company Secretary

Encl: a/a

Cc: 1. Krebs Biochemicals and Industries Limited
Plot No. 34, 8-2-577/B, Maas Heights,
Road No. 8, Banjara Hills, Hyderabad 500034
com_sec@krebbsbiochem.com

2. Audit Committee of Board of Directors of Krebs Biochemical & Industries Ltd..

Ipca Laboratories Ltd.
www.ipca.com